PW Medtech Group Limited disclosed on 8 September 2026 that it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 0.97 each, for a total consideration of HKD 48,500. All repurchased shares are designated for cancellation.

The transaction leaves the group’s issued share capital unchanged at 1.43 billion ordinary shares, as the newly repurchased stock has not yet been cancelled and no treasury shares are outstanding.

Including this latest trade, PW Medtech has bought back 3.31 million shares between 29 June and 8 September 2026 under the mandate approved on 26 June 2026. The cumulative repurchases represent 0.23% of the company’s issued share base on the mandate date and account for roughly 2.30% of the 144.29 million shares authorised for repurchase. The aggregate cash outlay since the mandate’s launch stands at approximately HKD 3.40 million, implying an average buy-back price of about HKD 1.03 per share.

Under Hong Kong listing rules, PW Medtech is subject to a moratorium on issuing new shares until 8 October 2026, 30 days after the most recent repurchase. The board confirmed that all repurchases have complied with the Hong Kong Stock Exchange’s regulations and the company’s existing explanatory statement dated 24 April 2026.